OpGen, Inc. provided revenue guidance for the year 2023. The company expects continue pursuing significant revenue growth opportunities, especially with Unyvero product sales and ARESiss services, both in the U.S. and internationally; expect global revenues from products, services and collaborations for 2023 to be in the range of approximately $4 million to $5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.442 USD | -5.96% | -5.96% | +5.24% |
Apr. 24 | OpGen Gets Notice of Noncompliance From Nasdaq | MT |
Mar. 26 | Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading | MT |
1st Jan change | Capi. | |
---|---|---|
+5.24% | 5.58M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- OPGN Stock
- News OpGen, Inc.
- OpGen, Inc. Provides Revenue Guidance for the Year 2023